Marshall Fordyce - 29 Dec 2023 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
President and CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
29 Dec 2023
Net transactions value
+$38,854
Form type
4
Filing time
03 Jan 2024, 16:15:04 UTC
Previous filing
23 Aug 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $1,196 +516 +0.21% $2.32 243,877 29 Dec 2023 Direct
transaction VERA Class A Common Stock Options Exercise $37,658 +13,000 +5.3% $2.90 256,877 29 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -516 -100% $0.000000* 0 29 Dec 2023 Class A Common Stock 516 $2.32 Direct F1
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -13,000 -1.5% $0.000000 874,212 29 Dec 2023 Class A Common Stock 13,000 $2.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of the shares subject to the option vested on January 10, 2021, and 1/36 of the shares vest monthly thereafter.
F2 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.